Does regenxbio stock pay dividends?
The company was formerly known as ReGenX Biosciences, LLC and changed its name to REGENXBIO Inc. in September 2014. REGENXBIO Inc. was founded in 2008 and is headquartered in Rockville, Maryland. More... RGNX does not currently pay a dividend.
What does regenxbio do for other companies?
REGENXBIO Inc. also licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies; and has a collaboration and license agreement with Neurimmune AG to develop vectorized antibodies for the treatment of neurodegenerative diseases.
Is regenxbio's rgx-202 a one-time gene therapy for Duchenne muscular dystrophy?
The FDA has granted Orphan Drug Designation to RegenXbio Inc's (NASDAQ: RGNX) RGX-202, potential one-time gene therapy for Duchenne muscular dystrophy (Duchenne). Duchenne is a genetic disorder characterized by progressive muscle degeneration and weakness due to the alterations of a protein called dystrophin that helps keep muscle cells intact.
What is RegeneRx Biopharmaceuticals?
What is RGRX in medical terms?
(OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, is addressing rumors in the market regarding its ARISE-3 phase 3 dry eye trial.
Is RegeneRx a biopharmaceutical company?
RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration), today announced that the results of the initial randomized, double-masked, placebo-controlled, phase 3 clinical trial of RGN-259 for the treatment of neurotrophic keratitis (SEER-1) will be presented at the 2021 American Ophthalmology Association meeting in New Orleans, LA on November 12-15. The results will be jointly presented by ReGenT
Is RegeneRx a joint venture?
RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration), today announced that GtreeBNT, the licensee for several RegeneRx products, is being acquired by HLB Group, a Korean company that includes six biopharmaceutical and financial subsidiaries in Korea and the U.S.
Investor Overview
RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration announced today that its joint venture, ReGenTree LLC, has enrolled the last of 700 subjects in the ARISE-3 phase 3 clinical trial for dry eye syndrome. Completion of treatment and follow-up for the last subject is anticipated to be by the end of November 2020. ReGenTree is a U.S. joint venture company owned by RegeneRx and GtreeBNT, a Korean biopharmaceutical company.
SEC Filings
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.
Does RGNX pay dividends?
No post was found with your current grid settings. You should verify if you have posts inside the current selected post type (s) and if the meta key filter is not too much restrictive.
Is Regenxbio on the NASDAQ?
RGNX does not currently pay a dividend.
Is RGNX bullish or bearish?
REGENXBIO Inc. is listed on the NASDAQ as (NASDAQ:RGNX).
Is RGNX bullish?
Currently, 6 Wall Street analysts rated RGNX as Bullish, while 0 were Bearish, and 2 rated it Neutral. This suggests a consensus of RGNX going up. View RGNX’s ratings here. 1 Seeking Alpha authors also rated the stock, and their ratings often outperform those of Wall Street analysts. Here are their ratings on RGNX
Powering a New Field of Discovery
8 analysts have issued ratings. Wall Street analysts rate RGNX as Bullish on average, for a Wall Street consensus of buy. View RGNX’s ratings here. 1 Seeking Alpha authors also rated the stock, and their ratings often outperform those of Wall Street analysts. Here are their ratings on RGNX
Patients & Families
REGENXBIO is seeking to improve lives through the curative potential of gene therapy. Our NAV ® Technology Platform has ushered in a new era of gene therapy innovation.
Partners & Licensees
We are deeply committed to discovering and developing innovative gene therapies to improve treatment options for people with severe and debilitating diseases with significant unmet needs.
What We Do
Partnerships and licensing are a key part of REGENXBIO’s commitment to enabling the ongoing development of gene therapy treatments using our NAV Technology Platform.
About ReGen Biologics
REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. Our gene therapy product candidates are designed to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins that are intended to impact disease.
Who are some of ReGen Biologics' key competitors?
ReGen Biologics, Inc. provides decision support information systems and consulting services to the health care industry. It offers outcomes-based products and services. The company's technology focuses on guided tissue generation. ReGen Biologics was founded by Shu-Tung Li on September 1, 1987 and is headquartered in Hackensack, NJ.
What is ReGen Biologics' stock symbol?
Some companies that are related to ReGen Biologics include Adynxx (ADYX), G Medical Innovations (GMVD), Icecure Medical (ICCM), LifePoint (LFPI), Paradigm Medical Industries (PDMI), ProUroCare Medical (PUMD), Quick-Med Technologies (QMDT), Revolutions Medical (RMCP), Scivanta Medical (SCVM), Speedus (SPDE), Spinal Elements (SPEL), StatSure Diagnostic Systems (SSUR) and Vasamed (VSMD). View all of RGBOQ's competitors..
How do I buy shares of ReGen Biologics?
ReGen Biologics trades on the OTCMKTS under the ticker symbol "RGBOQ."
Where are ReGen Biologics' headquarters?
Shares of RGBOQ can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here.
